MAbSilico has deeptech scientists
deeptech scientists
A French deeptech company designing and implementing computational solutions for therapeutic antibodies and biodrugs discovery and development. MAbSilico provides a formal embedded technology for antibody discovery, reducing the risks of failure and the duration of discovery and preclinical steps, as well as strengthening intellectual property protection. Conventional approaches for drug discovery take up to three years, while MAbSilico technologies allow shrinking this time to a few weeks.
Sciences domains
Computational biology
Immunology expertise
Biological data mining
Business mentoring
Business development
High-tech entrepreneur
a full ecosystem team
MAbSilico is the best combination of computational scientists and biologists. The AI-based technologies are validated and improved in our wet-lab facility to generate a product ready to the market. The team gathers more than 100 scientific publications, and 4 patents. Our scientific and advisory board englobes KOLs and entrepreneurs with a vision to change antibody design and discovery.
Executive team
Advisory board
LabEx, MabImprove
OSE Immunotherapeutics
IPSEN
Anne POUPON - CTO
is a PI at CNRS with more than 20 years of experience in computational science., She holds a PhD in biomathematics, worked in the best French institutes (CEA, INRA, CNRS) and published more than 70 scientific papers in biology and computational journals. She was leader of the research group at INRA/CNRS where the co-founders met and developed the technologies used by MAbSilico.
Thomas BOURQUARD - CSO
did his PhD with Anne Poupon at Paris-Saclay, worked at INRIA, INRA and joined the Baylor College of Medicine in Huston, Texas, where he is involved in Intelligence Advanced Research Projects Activity (IARPA) programs.
Astrid MUSNIER - Head of biology
The computational technologies are experimentally validated by Astrid Musnier (head of biology). She holds a PhD in biology, has strong expertise in protein interaction and GPCR, and worked with Anne Poupon and Thomas Bourquard in the INRA/CNRS lab. She worked at the Hunter College in New-York to decipher the mechanism of action of FMRP a protein involved in autistic fragile X syndrome before coming back in France and co-found MAbSilico.
Vincent PUARD - CEO
He holds a PhD in biomedicine and collaborated with Anne Poupon’s team during his PhD. He joined a biotech company (Avacta Life Sciences) with a ITN Marie Curie fellowship prior working for research institutes like LIH and Institut Curie, developing high throughput technology for protein selection and characterization (including antibody technology). His managerial and business skills were developed during his functions as head of technology and head of platform and with trainings like the MOCC X-HEC.
Samuel DOMINIQUE - COO
These 4 co-founders were joined in 2019 by Samuel Dominique, a serial entrepreneur in embedded software in aeronautics, defence & space, with a strong background for disruptive technology development transformation into product and commercialization to major industrials. His knowledge in software industry and cybersecurity accelerates the go to market to scale-up MAbSilico and deliver a product that fits the requirements of pharma companies.The board
The company board includes KOLs in immune-oncology from academia: Prof. Hervé Watier, head of the LabEx MabImprove, and from industry: Dr. Nicolas Poi r ier from OSE Immunotherapeutics, Dr. Thierry Wurch from IPSEN, and corporate investment: Nicolas Felix from Vermon.
LabEx
MabImprove coordinator
Immunotherapeutics
IPSEN
Business partners
MAbSilico’s technologies are already used by customers for the development of therapeutic antibodies. Our Business partners have a clear vision for the future and the will to make a difference. They are ready to adopt our technologies and implement AI in their discovery processes.
Partnerships
Our partners share clear vision and a desire to make a difference. Fantastic teams are made up of empowered individuals. We don’t preach, we are conversation starters. Often, growth is fast, and we need to make changes, faster.
Contact us
